European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
Voice outcomes after office-based hyaluronic acid injection for vocal fold immobility: a prospective single-center study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Forges Clémence, Rigal Tiffany, Circiu Marta P, Nicolleau Stanislas, Crevier-Buchman Lise, Mailly Marie, Julien-Laferrière Aude, Vialatte de Pémille Grégoire, Remacle Marc, Lechien Jérôme R, Baudouin Robin, Hans Stéphane
Аннотация
OBJECTIVE: To assess the short-term voice quality in unilateral vocal fold paralysis (UVFP) patients after office-based hyaluronic acid injection laryngoplasty (OBIL) using the European Laryngeal Society (ELS) multidimensional voice quality assessment.
METHODS: Patients with UVFP that underwent OBIL were prospectively recruited from November 2022 to November 2024, at a tertiary university medical center (laryngology unit). Voice handicap index (VHI), GRBAS perceptual evaluation, maximum phonation time (MPT), and acoustic parameters were evaluated seven days and one month post-OBIL. Videolaryngostroboscopy was evaluated to assess the glottic closure (complete or incomplete) using the ELS recommendations.
RESULTS: Thirty-two patients with UVFP were included. The amount of injectable ranged from 0.2 mL to 0.8 mL. Improvement in glottal closure was observed in 22/32 (75%) patients at Day-7 and 21/32 (68.8%) at one month post-OBIL. VHI significantly decreased after injection (p = 0.02). Other vocal outcomes (f0, percent jitter, percent shimmer, harmonic to noise ratio) revealed non-significant improvements (p > 0.05). MPT did not change (p = 0.37). Perceptual outcomes decreased non-significantly following OBIL, with 'breathiness' improving the most (p > 0.05).
CONCLUSION: OBIL improves voice quality in patients with UVFP. All voice quality outcomes show early improvement at Day-7 and continue to improve at Month-1 after injection. VHI emerged as the most sensitive tool for detecting voice changes.
METHODS: Patients with UVFP that underwent OBIL were prospectively recruited from November 2022 to November 2024, at a tertiary university medical center (laryngology unit). Voice handicap index (VHI), GRBAS perceptual evaluation, maximum phonation time (MPT), and acoustic parameters were evaluated seven days and one month post-OBIL. Videolaryngostroboscopy was evaluated to assess the glottic closure (complete or incomplete) using the ELS recommendations.
RESULTS: Thirty-two patients with UVFP were included. The amount of injectable ranged from 0.2 mL to 0.8 mL. Improvement in glottal closure was observed in 22/32 (75%) patients at Day-7 and 21/32 (68.8%) at one month post-OBIL. VHI significantly decreased after injection (p = 0.02). Other vocal outcomes (f0, percent jitter, percent shimmer, harmonic to noise ratio) revealed non-significant improvements (p > 0.05). MPT did not change (p = 0.37). Perceptual outcomes decreased non-significantly following OBIL, with 'breathiness' improving the most (p > 0.05).
CONCLUSION: OBIL improves voice quality in patients with UVFP. All voice quality outcomes show early improvement at Day-7 and continue to improve at Month-1 after injection. VHI emerged as the most sensitive tool for detecting voice changes.